Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors

Risk factors for hepatic immune-related adverse events (HIRAEs) in patients with advanced/unresectable hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are unclear. We investigated: (i) clinical and morpho-pathological predictors of HIRAEs in 27 pretreatment tumor spec...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicola Personeni, Tiziana Pressiani, Antonio D’Alessio, Maria Giuseppina Prete, Silvia Bozzarelli, Luigi Terracciano, Arianna Dal Buono, Antonio Capogreco, Alessio Aghemo, Ana Lleo, Romano Fabio Lutman, Massimo Roncalli, Laura Giordano, Armando Santoro, Luca Di Tommaso, Lorenza Rimassa
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	hepatotoxicity hepatocellular carcinoma immune checkpoint inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3222d708afd849bdbecd0208aa93d8c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors

Ejemplares similares